ent-11,16-Epoxy-15-hydroxykauran-19-oic acidCAS# 77658-46-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 77658-46-9 | SDF | Download SDF |
| PubChem ID | 102004619 | Appearance | Powder |
| Formula | C20H30O4 | M.Wt | 334.5 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (1R,4S,5R,9R,10S,11S,13R,14R,16S)-16-hydroxy-5,9,13-trimethyl-12-oxapentacyclo[11.2.1.111,14.01,10.04,9]heptadecane-5-carboxylic acid | ||
| SMILES | CC12CCCC(C1CCC34C2C5CC(C3)C(C4O)(O5)C)(C)C(=O)O | ||
| Standard InChIKey | RNEBMVMFRKVVMY-GOCTUUHOSA-N | ||
| Standard InChI | InChI=1S/C20H30O4/c1-17-6-4-7-18(2,16(22)23)13(17)5-8-20-10-11-9-12(14(17)20)24-19(11,3)15(20)21/h11-15,21H,4-10H2,1-3H3,(H,22,23)/t11-,12-,13-,14-,15+,17+,18+,19+,20+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
ent-11,16-Epoxy-15-hydroxykauran-19-oic acid Dilution Calculator
ent-11,16-Epoxy-15-hydroxykauran-19-oic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9895 mL | 14.9477 mL | 29.8954 mL | 59.7907 mL | 74.7384 mL |
| 5 mM | 0.5979 mL | 2.9895 mL | 5.9791 mL | 11.9581 mL | 14.9477 mL |
| 10 mM | 0.299 mL | 1.4948 mL | 2.9895 mL | 5.9791 mL | 7.4738 mL |
| 50 mM | 0.0598 mL | 0.299 mL | 0.5979 mL | 1.1958 mL | 1.4948 mL |
| 100 mM | 0.0299 mL | 0.1495 mL | 0.299 mL | 0.5979 mL | 0.7474 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- ent-9-Hydroxy-15-oxo-19-kauranoic acid
Catalog No.:BCN1356
CAS No.:77658-45-8
- ent-9-Hydroxy-15-oxo-16-kauren-19-oic acid
Catalog No.:BCN1357
CAS No.:77658-39-0
- Pterokaurene L3
Catalog No.:BCN4583
CAS No.:77658-38-9
- Boc-D-Ala-OH
Catalog No.:BCC3049
CAS No.:7764-95-6
- Toddanone
Catalog No.:BCN3430
CAS No.:77636-08-9
- 1,4,5,6-Tetrahydroxy-7,8-diprenylxanthone
Catalog No.:BCN1358
CAS No.:776325-66-7
- Fmoc-HomoArg-OH
Catalog No.:BCC2645
CAS No.:776277-76-0
- Isoscopoletin
Catalog No.:BCN4582
CAS No.:776-86-3
- Nestoron
Catalog No.:BCC1797
CAS No.:7759-35-5
- Ingenol-3,4:5,20-diacetonide
Catalog No.:BCN2959
CAS No.:77573-44-5
- Ingenol-5,20-acetonide
Catalog No.:BCN2960
CAS No.:77573-43-4
- (20R)-Protopanaxdiol
Catalog No.:BCN1078
CAS No.:7755-01-3
- Enoximone
Catalog No.:BCC7155
CAS No.:77671-31-9
- 6'''-Feruloylspinosin
Catalog No.:BCN2802
CAS No.:77690-92-7
- Arctigenin
Catalog No.:BCN6291
CAS No.:7770-78-7
- (-)-Toddanol
Catalog No.:BCN3429
CAS No.:77715-99-2
- 1,7-Dihydroxy-3-methoxy-2-prenylxanthone
Catalog No.:BCN1354
CAS No.:77741-58-3
- 1,2-Dihydrotanshinquinone
Catalog No.:BCN2477
CAS No.:77769-21-2
- Potassium phosphate monobasic
Catalog No.:BCC7583
CAS No.:7778-77-0
- Dehydrocrebanine
Catalog No.:BCN4328
CAS No.:77784-22-6
- Carasinol B
Catalog No.:BCN8226
CAS No.:777857-86-0
- GNF 2
Catalog No.:BCC3891
CAS No.:778270-11-4
- GNF 5
Catalog No.:BCC3892
CAS No.:778277-15-9
- Nelumol A
Catalog No.:BCN4749
CAS No.:77836-86-3
Induction of laryngeal cancer cell death by Ent-11-hydroxy-15-oxo-kaur-16-en-19-oic acid.[Pubmed:20146336]
Head Neck. 2010 Nov;32(11):1506-18.
BACKGROUND: Ent-11-hydroxy-15-oxo-kaur-16-en-19-oic acid (5F) is known to exhibit antitumor activity, but its mechanism is not completely understood. 5F has not been tested in laryngeal cancer. METHODS: Two laryngeal cancer cell lines were treated with 5F. Cell death was analyzed by MTT [3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide] and Annexin V assay. Nuclear factor kappa beta (NF-kappaB)- and apoptosis-related molecules were examined. RESULTS: 5F induced laryngeal cancer cell death in a dose-dependent manner. The Annexin V assay and the measurement of cleavage of procaspase-3 and poly(ADP-ribose) polymerase demonstrated that the 5F-induced cell death was mainly apoptotic. 5F slightly reduced the basal level of NF-kappaB, but significantly suppressed the inducible NF-kappaB by reducing its transcriptional activity, protecting its inhibitory subunit IkappaBalpha from degradation, and suppressing its level in the nucleus. 5F also inhibited pro-proliferative and anti-apoptotic molecules but promoted pro-apoptotic Bax. CONCLUSIONS: 5F induces apoptosis of laryngeal cancer cells by inhibiting NF-kappaB activation/induction, suppressing pro-proliferative and anti-apoptotic molecules, and promoting pro-apoptotic Bax.
[ROS is not involved in induction of cell death by Ent-11 alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid in HepG2 cells].[Pubmed:20707199]
Zhongguo Zhong Yao Za Zhi. 2010 May;35(10):1287-91.
OBJECTIVE: To identify the role of reactive oxygen species (ROS) formation on cell death induced by Ent-11alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F) in HepG2 cells. METHOD: MTT assay was used to determine the effect of 5F on proliferation of HepG2 cells, and apoptotic morphological changes were assessed using Hoechst/PI assay. To evaluate intracellular ROS levels, a GENMED kit was used. HepG2 cells were treated with 5F for 24 h or with 1 mmol x L(-1) GSH for 1 h prior to treatment with 5F for 24 h, then cytoplasmic mono- and oligonucleosomes were assessed with Cell Death Detection ELISA kit. RESULT: The cytotoxicity of 5F on HepG2 cells was elevated with increasing 5F concentrations, as evidenced by the cell viability assay, and the apoptotic changes such as chromatin condensation were confirmed by Hoechst/PI staining. The decrease in ROS generation was observed in HepG2 cells following treatment with 5F. Cytoplasmic mono- and oligonucleosomes induced by 5F were not changed by decreasing basal level of ROS-mediated signaling with GSH. Further more, induction of ROS production by cisplatinum (CDDP) was canceled by treatment with 5F and 5F revealed a additive effect to cell killing by CDDP. CONCLUSION: 5F can not only induce apoptosis through non-ROS-depandent pathway, and can abate oxidant stress.
